Who are Nandrolon's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nexplanon, Ortho-Cept, Danzol, Nandrolone Decanoate, Intrarosa, Benzofoline.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nandrolone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Nandrolon — Competitive Intelligence Brief

Nandrolon (NANDROLONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Androgen. Area: Hematology.

marketed Androgen Sex hormone-binding globulin Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Nandrolon (NANDROLONE).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nandrolon TARGET	NANDROLONE		marketed	Androgen	Sex hormone-binding globulin
Nexplanon	ETONOGESTREL		marketed	Estrogen [EPC]	Sex hormone-binding globulin	2001-01-01
Ortho-Cept	DESOGESTREL	Merck & Co.	marketed	Progestin	Sex hormone-binding globulin	1992-01-01
Danzol	DANAZOL		marketed	Androgen [EPC]	Sex hormone-binding globulin	1976-01-01
Nandrolone Decanoate	NANDROLONE DECANOATE	Woodward Specl	marketed	Androgen	Sex hormone-binding globulin	1962-01-01
Intrarosa	PRASTERONE		marketed	Non-Standardized Food Allergenic Extract [EPC]	Sex hormone-binding globulin
Benzofoline	ESTRADIOL BENZOATE		marketed	Estrogen	Adenosine receptor A3, Sex hormone-binding globulin, 5-hydroxytryptamine receptor 2B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Androgen class)

· 4 drugs in this class
Azurity · 1 drug in this class
Endo · 1 drug in this class
Marius · 1 drug in this class
Merck & Co. · 1 drug in this class
The Affiliated Hospital of Qingdao University · 1 drug in this class
Woodward Specl · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nandrolon — Competitive Intelligence Brief. https://druglandscape.com/ci/nandrolone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab